Final Research and Development Reports Sample Clauses
The 'Final Research and Development Reports' clause requires the completion and submission of comprehensive reports summarizing all research and development activities conducted under an agreement. Typically, this clause specifies the format, content, and deadline for delivering these final reports, which may include data, results, methodologies, and any intellectual property developed. Its core function is to ensure that the contracting party receives a complete record of the work performed, facilitating knowledge transfer, compliance, and potential future use or commercialization of the results.
Final Research and Development Reports. The Parties will exchange final reports of their results within six (6) months after the expiration or termination of this CRADA. These reports will set forth the technical progress made; any publications arising from the research; and the existence of invention disclosures of potential CRADA Subject Inventions and/or any corresponding Patent Applications.
Final Research and Development Reports. ICD and Collaborator will share CRADA Data as it is developed pursuant to the Research Plan, and will provide final reports of the results of non-clinical studies [***] of the completion of the study and final reports of the results of clinical trials [***] of the completion of the trial if available. Collaborator may contract directly with the extramural Clinical Investigators for preparation of a final report if no publication is provided. The Parties will exchange final reports of their results [***] after the expiration or termination of this CRADA. These reports will set forth the technical progress made; any publications arising from the research; and the existence of invention disclosures of potential CRADA Subject Inventions and/or any corresponding Patent Applications. Abstracts and publications provided to CTEP by investigators and further provided by CTEP to Collaborator will fulfill this final report obligation. Source documents from clinical studies under this CRADA containing Raw Data in the possession of either Party
Final Research and Development Reports. The Parties will exchange final reports of their results within six (6) months after the expiration or termination of this CRADA. These reports will set forth the technical progress made; any publications arising from the research; and the existence of invention disclosures of potential CRADA Subject Inventions and/or any corresponding Patent Applications. Abstracts and publications provided to CTEP by investigators and further provided by CTEP to Collaborator will fulfill this final report obligation. With respect to clinical studies, a copy of the IND Annual Report will also fulfill this reporting obligation. Confidential NCI – Tracon CRADA (NCI# 02663), Appendix C Article 4.4 is modified to read as follows:
Final Research and Development Reports. The Parties will exchange final reports of their results within four (4) months after the expiration or termination by mutual consent of this CRADA or four (4) months after Leidos Biomedical ends work on the Joint Work Statement in case of unilateral termination by Collaborator. These reports will set forth the technical progress made, any publications arising from the research, and the existence of invention disclosures of potential CRADA Subject Inventions and/or any corresponding Patent Applications.
Final Research and Development Reports. IC will provide to Collaborator final reports of the results of all studies conducted under the Research Plan as they become available and, for those final reports that have not been provided by IC during the term of the CRADA, within six (6) months after the expiration or termination of this CRADA. These reports will set forth the technical progress made; any publications arising from the research; and the existence of invention disclosures of potential CRADA Subject Inventions and/or any corresponding Patent Applications. [ * ].
Final Research and Development Reports. The Parties will exchange final clinical study reports promptly (but no later than [.***.]) following data lock for the clinical study under this CRADA. These reports will set forth the technical progress made; any publications proposed to be made on results arising from the research; and the existence of invention disclosures of potential CRADA Subject Inventions and/or any corresponding Patent Applications.
Final Research and Development Reports. The Parties will exchange final reports of their results within [***] after the expiration or termination by mutual consent of this CRADA or [***] after Leidos Biomedical ends work on the Joint Work Statement in case of unilateral termination by Collaborator. These reports will set forth the technical progress made, any publications arising from the research, and the existence of invention disclosures of potential CRADA Subject Inventions and/or any corresponding Patent Applications.